Site icon pharmaceutical daily

LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 2025

BusinessWire

BALLERUP, Denmark–(BUSINESS WIRE)–NOT FOR UK USE – NOT INTENDED FOR UK MEDIA


LEO Pharma A/S, a global leader in medical dermatology, will unveil its most ambitious and innovation-driven scientific program to date at the 34th European Academy of Dermatology and Venereology (EADV) Congress, held from 17-20 September in Paris, France.

Notably, for the second year in a row, LEO Pharma is noted for 5 late-breaking presentations – corresponding to roughly 1 in 7 out of the possible 36 EADV late-breakers – demonstrating the company’s leading role in medical dermatology.

“It is truly inspiring to witness the depth and diversity of our scientific contributions at this year’s EADV Congress. Five late-breakers – for the second year in a row – in addition to our highest ever number of abstracts makes this a record-breaking contribution from us and a clear demonstration of our unwavering commitment to shaping the future of dermatology. LEO Pharma has the broadest global portfolio in medical dermatology – and this year’s scientific contribution at EADV reflects this across disease areas, applications and global markets, truly demonstrating our role as a global leader,” said Christophe Bourdon, CEO of LEO Pharma.

With a total of 5 late-breaking presentations, 24 regular abstracts, and 1 symposium, LEO Pharma’s presence at the 2025 EADV Congress represents its largest and most comprehensive scientific contribution to date, underscoring the company’s commitment to make a fundamental difference in medical dermatology worldwide.1-29

“I am both proud and excited to share our latest scientific advances at this year’s EADV Congress. The breadth of our programme — covering multiple disease areas from atopic dermatitis and chronic hand eczema to psoriasis — reflects LEO Pharma’s commitment to innovation across a wide portfolio. Our pipeline also includes therapies for rare and less common skin diseases underscoring our responsibility as a global leader to drive meaningful innovation for all patients,” said Jacob P. Thyssen, Chief Scientific Officer & Executive Vice President, Science, Search & Innovation at LEO Pharma.

For the second year in a row, LEO Pharma is present at EADV with 5 late-breaker presentations1-5, which include:

Furthermore, the full roster of new and encore abstracts6-29 and symposiums at the 2025 EADV congress includes:

Delgocitinib:

Tralokinumab:

Temtokibart:

Brodalumab:

Calcipotriol/betamethasone:

In addition to the abstracts and poster presentations, LEO Pharma will also present a symposium at the EADV Congress:

About Chronic Hand Eczema

Chronic Hand Eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.30,31 CHE is one the most common skin disorder of the hands with a global prevalence rate of approximately 4.7%.32 In a substantial number of patients, HE can develop into a chronic condition.33 CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.34

CHE has been shown to cause psychological and functional burdens that impact patient quality of life,35 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition.36 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.37

About Atopic Dermatitis

Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.38 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.39 Type 2 cytokines, including IL-13, play an important role in the key aspects of atopic dermatitis pathophysiology.38,39 Excessive IL-22 production is also known to contribute to the pathogenesis of AD.40

About Psoriasis

Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide.41,42 Psoriasis is the result of skin barrier cell proliferation and the activation of cytokines (a family of proteins involved in immune responses) that cause inflammation.43 About 80% to 90% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis.44 The symptoms of plaque psoriasis are itchy or painful raised scaly and inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso.44

About ANZUPGO® (delgocitinib) Cream

ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.45

ANZUPGO is approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. ANZUPGO cream is also under investigation in other markets.

ANZUPGO® (delgocitinib) cream is also FDA approved in the U.S for moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.46

In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.

About Adtralza® (tralokinumab) / Adbry ® (tralokinumab-ldrm)

Adtralza® (tralokinumab), which is marketed under the tradename Adbry® in the U.S., is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin IL-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.39,47 Adtralza® specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).48

Adtralza® is approved for the treatment of moderate to severe AD in adult and adolescent patients 12 years and older in the U.S, European Union, Canada, Great Britain, the United Arab Emirates, and South Korea. Adtralza® is approved for use in adults with moderate to severe AD in Switzerland, Saudi Arabia, and Japan.

About Kyntheum® (brodalumab)

Kyntheum® (brodalumab) is a recombinant fully human monoclonal immunoglobulin IgG2 antibody that binds with high affinity to human IL-17RA and blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C and IL-17E (also known as IL-25), resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. IL-17 family cytokine levels have been reported to increase in psoriasis. IL-17A, IL-17F and IL-17A/F heterodimer have pleiotropic activities including the induction of pro-inflammatory mediators such as IL-6, GROα, and G-CSF from epithelial cells, endothelial cells and fibroblasts that promote tissue inflammation. IL-17C has been shown to induce similar responses as IL-17A and IL-17F in keratinocytes. Blocking IL-17RA inhibits IL-17 cytokine-induced responses resulting in normalization of inflammation in the skin.49

Kyntheum® is indicated in the European Union, Great Britain, the United Arab Emirates, and Brazil for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

About temtokibart

Temtokibart (LEO 138559) is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate to severe atopic dermatitis.50 It blocks the IL-22RA1 subunit and thereby inhibits the effects of the IL-22 cytokine, and potentially also to some extent the effects of IL-20 and IL-24.50 Temtokibart does not bind to the IL-22 cytokine itself.50 LEO Pharma has obtained a worldwide exclusive license to develop and commercialize temtokibart from argenx.

About Enstilar®

Enstilar® is an aerosol spray foam containing calcipotriol monohydrate 50 mcg/g and betamethasone dipropionate 0.5 mg/g. In the EU, it is indicated for the treatment of psoriasis vulgaris in adults for up to 4 weeks. Patients who have responded at 4 weeks’ treatment using Enstilar once daily are suitable for long-term maintenance treatment. 51-54 In the US, it is indicated for the treatment of psoriasis vulgaris in patients from 12 years and older.

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.

References

  1. Molin S, et al. DELTA TEEN trial: Efficacy and Safety of Delgocitinib Cream in Adolescents with Moderate to Severe Chronic Hand Eczema. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. Oral Presentation. D2T01.3B.
  2. Bissonnette R, et al. Safety of delgocitinib cream in adult patients with moderate to severe CHE: pooled analysis of five phase 2b and phase 3 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. Oral Presentation. D2T01.3E.
  3. Weidinger S, et al. IL-22RA1 antagonism with temtokibart provides significant early and sustained improvements in atopic dermatitis: results from a phase 2b dose-finding trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. Oral Presentation. D1T01.1E.
  4. Del Duca E, et al. Temtokibart, an IL-22RA1 Monoclonal Antibody broadly dampens gene expression markers of activated immune pathways in Atopic Dermatitis: Results from a Phase 2b Trial Subgroup Analysis. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. Oral Presentation. D1T01.1F.
  5. Blauvelt A, et al. Initial “Super Response” to Tralokinumab Leads to Stable Long-term Response in Patients with Moderate-to-Severe Atopic Dermatitis: Responder and Predictor Analysis from the ECZTRA 3 & ECZTEND Trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. Oral Presentation. D3T01.3F.
  6. Agner T, et al. Treatment with delgocitinib cream is associated with a reduction of Staphylococcus aureus density and pain in patients with mild to severe CHE. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. EPS03.
  7. Bissonnette R, et al. Delgocitinib cream improves pain and health-related quality of life in patients with CHE with severe pain. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0358.
  8. Armstrong A, et al. Matching-Adjusted Indirect Comparison of the Efficacy at week 12 of Delgocitinib and topical PUVA in the treatment of Severe CHE. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P2798.
  9. Schuttelaar ML, et al. CHE has a Profound Impact on Daily Life, Social Interactions and Emotional Wellbeing: Results from a Global Patient Survey. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P2800.
  10. Fargnoli MC, et al. Aetiological subtypes of moderate to severe CHE: Signs, symptoms and localisations -Results from the RWEAL study. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0627.
  11. Halioua B, et al. Burden of CHE in France Using the French Nationwide Claims Database. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P3280
  12. Armstrong AW, et al. Patient perspectives in moderate to severe CHE: Understanding patient experience and factors influencing treatment preference through in-depth qualitative patient interviews in the US. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0284.
  13. Crepy MN, et al. CHE in France: Expert Insights. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P3738.
  14. Armstrong A, et al. “Super-response” following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe Chronic Hand Eczema. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0312.
  15. Bissonnette R, et al. Patient reported outcome measures and symptom improvements across subtypes of Chronic Hand Eczema: outcomes from the Phase 3 DELTA-1 and DELTA-2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0311.
  16. Stein Gold L, et al. Delgocitinib cream is well tolerated in Chronic Hand Eczema: DELTA 1 and 2 pooled analysis. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0306.
  17. Eichenfield LF, et al. Delgocitinib cream 20 mg/g in Chronic Hand Eczema patients with skin fissures: efficacy, safety, and pharmacokinetics. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0308.
  18. Mohandas P, et al. Clinical trial exit interviews in patients with moderate to severe Chronic Hand Eczema: evaluation of treatment experiences with delgocitinib cream 20 mg/g in the phase 3 DELTA 1 trial (no. 1455). Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0280.
  19. Yu J, et al. Delgocitinib cream provides early and meaningful responses in adults with moderate to severe Chronic Hand Eczema: a pooled analysis of the phase 3 DELTA-1 and DELTA-2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0307.
  20. Bunick C, et al. Delgocitinib cream formulation development for Chronic Hand Eczema (CHE): insights from patient preference and skin penetration studies. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0309.
  21. Ehst B, et al. Delgocitinib cream leads to significant improvements across all Chronic Hand Eczema signs and region HECSI subscores in the phase 3 DELTA-1 and DELTA-2 trials. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. Paris, France. 17–20 September. ePoster Presentation. P0310.

Contacts

Jes Broe Frederiksen
LEO Pharma, Senior Manager, Global Product and Data Communications

Tel: +45 53 60 59 48

Email: jebfe@leo-pharma.com

Read full story here

Exit mobile version